Comparing the current results to its competitors, Agilent Technologies Inc reported Revenue increase in the 2 quarter 2026 by 10.01 % year on year. The sales growth was above Agilent Technologies Inc 's competitors' average revenue growth of 9.3 %, achieved in the same quarter.
Agilent Technologies inc Net Income in the 2 quarter 2026 grew year on year by 57.67%, faster than the Agilent Technologies Inc 's competitors average income growth of 15.55 %
Agilent Technologies Inc 's Comment on Competition and Industry Peers
The company operates in the Life Sciences and Diagnostics Markets and the Applied Markets segments, both of which feature evolving industry standards and significant competition. Key competitors in the Life Sciences and Diagnostics Markets include AB Sciex (a division of Danaher Corporation), Avecia (a division of Nitto Denko), Bruker, Inc., Leica Biosystems, Inc. (a division of Danaher Corporation), Roche Ventana Medical Systems, Inc. (part of the Roche Group), Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, and Waters Corporation. In the Applied Markets segment, principal competitors include Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., Waters Corporation, and various niche service providers. Competition in these segments is based on product performance, reliability, support quality, applications expertise, global channel coverage, and price.
Company's competitiveness improved within Overall company, with revenue growth of 10.01 % and its market share increased to approx. 2.28 %. << More on A Market Share.
*Market share is calculated based on total revenue.
August 2, 2024
In a significant advancement for cancer diagnostics and treatment, Agilent Technologies Inc. has announced the receipt of FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032). This advancement heralds a crucial step towards enhancing patient care in those diagnosed with synovial sarcoma, a rare and aggressive form of cancer. By enabling clinicians to identify patients who may benefit from the recently approved TCR T-Cell therapy, TECELRA (afamitresgene autoleucel, also referred to as afami-cel or ADP-A2M4), Agilent s diagnostic tool stands to improve therapeutic outcomes for this difficult-to-treat demographic. Understanding MAGE-A4 and Its Clinical SignificanceMAGE-A4, or melanoma-associated antigen A4, is ...
May 1, 2024
Agilent Technologies Inc. has unveiled its latest groundbreaking innovation, the NovoCyte Opteon Spectral Flow Cytometer, propelling the field of flow cytometry into a new era of accessibility and advancement. This state-of-the-art system sets a new gold standard for acquiring, analyzing, and reporting flow data across various domains, from basic research to drug discovery and therapy development.The NovoCyte Opteon represents a significant leap forward in flow cytometry, offering a range of configurations to cater to different requirements. Its cutting-edge technology enables researchers to achieve unparalleled accuracy and efficiency in their experiments. By providing comprehensive and accurate flow data a...
January 30, 2024
Agilent Technologies Collaborates with Incyte to Propel Advanced Companion Diagnostics in Hematology and OncologySANTA CLARA, Calif. - In a groundbreaking partnership, Agilent Technologies Inc. (NYSE: A) and Incyte have joined forces to harness Agilent s renowned expertise in developing companion diagnostics (CDx) and apply it to the advancement and commercialization of Incyte s remarkable hematology and oncology portfolio. With the companion diagnostics market predicted to soar to almost US $14 billion by 2030, the potential impact of these tests in informing treatment decisions cannot be understated.The collaboration between Agilent Technologies and Incyte represents a significant step forward in the devel...
December 20, 2023
Agilent Technologies Restructures Organizational Structure to Drive Growth OpportunitiesAgilent Technologies Inc. recently announced strategic updates to its organizational structure by integrating the Cell Analysis Division into its Diagnostics and Genomics Group (DGG). This move aims to enhance growth opportunities for both divisions and capitalize on the synergies between the markets they serve.According to Mike McMullen, Agilent s president and CEO, incorporating the cell analysis team into DGG is a logical step due to the clear linkages with the company s genomics and diagnostics customers. This strategic realignment positions Agilent Technologies to leverage its expertise in these areas and strengthen ...
In a recent announcement, Agilent Technologies Inc. has unveiled significant advancements in its BioTek Cytation C10 confocal imaging reader. The addition of water immersion and new confocal spinning disk technology has revolutionized image quality and results, mitigating negative impacts on live-cell samples and enhancing clarity for thicker samples like tissues and 3-D spheroids. Water immersion technology, a crucial feature in light microscopy, consistently creates a layer of water to further enhance image quality. By implementing this innovative solution, Agilent Technologies sets itself apart from competitors in terms of performance and reliability. The improved image quality and reduced delete...
Tower Semiconductor Ltd is a leading global specialty foundry company that provides advanced technology and manufacturing solutions for integrated circuits (ICs) in sectors such as consumer electronics, automotive, medical, and more. The company operates on a fabless business model, partnering with customers to develop and manufacture their ICs on Tower's advanced semiconductor manufacturing platform.
10x Genomics Inc is a biotechnology company that specializes in providing tools and solutions for genomic research. Their business model revolves around developing innovative technologies and platforms to enable scientists and researchers to gain deeper insights into the structure and function of biological systems. They offer products such as single-cell sequencing and spatial transcriptomics to support various areas of genomics research and accelerate discoveries in fields like cancer research, immunology, and neuroscience.
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
Sources:
Agilent Technologies inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Agilent Technologies inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
